deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT04659174

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

An Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 Schizophrenia

Sponsor: Karuna Therapeutics

Conditions Schizophrenia
Interventions Xanomeline and Trospium Chloride Capsules
Updated 19 times since 2021 Last updated: Oct 2, 2024 Started: Feb 1, 2021 Primary completion: Oct 3, 2023 Completion: Oct 3, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Schizophrenia and is currently completed. Karuna Therapeutics leads this study, which shows 19 recorded versions since 2021 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Nov 2022 · 5 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Nov 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 14 earlier versions

  1. Apr 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  4. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  5. Jun 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  6. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  7. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  8. Nov 2021 — Apr 2022 [monthly]

    Recruiting PHASE3

  9. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  10. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  11. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  12. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  13. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  14. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Karuna Therapeutics
Data source: Karuna Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Atlanta, United States , Austin, United States , Bellflower, United States , Bentonville, United States , Berlin, United States , Chicago, United States , Culver City, United States , DeSoto, United States , Decatur, United States and 28 more locations